U.S. FDA flags risk of heart inflammation after Novavax COVID vaccine | Reuters
U.S. Food and Drug Administration staff said on Friday they were concerned about a possible risk of heart inflammation from Novavax Inc's vaccine, even as the company's data showed the vaccine was effective in reducing the risk of mild-to-severe COVID-19.